NCT05920018View on ClinicalTrials.gov

Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 2, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DIETARY_SUPPLEMENT

Vivomixx®

Daily application of four sachets, i.e. 1.800 bio bacteria/day for 48 weeks

DIETARY_SUPPLEMENT

Conjugated linoleic acid (CLA/Tonalin® FFA 80)

Daily application of two capsules p.o., i.e. 2g/day for 48 weeks

OTHER

Maltose placebo

Daily application of four sachets for 48 weeks

OTHER

Sunflower oil placebo

Daily application of two capsules p.o for 48 weeks

Trial Locations (4)

49076

RECRUITING

Klinikum Osnabrück GmbH, Klinik für Neurologie, Osnabrück

69120

RECRUITING

Universitätsklinik Heidelberg, Neurologische Klinik, Heidelberg

Unknown

RECRUITING

Neurological study centre, Department of Neurology, Mainz

RECRUITING

IIT unit of the Department of Neurology with Institute of Translational Neurology, Münster

All Listed Sponsors
lead

Universität Münster

OTHER